Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity

被引:169
作者
Jakobsen, A [1 ]
Nielsen, JN [1 ]
Gyldenkerne, N [1 ]
Lindeberg, J [1 ]
机构
[1] Vejle Hosp, Dept Oncol, Danish Colorectal Canc Grp S, DK-7100 Vejle, Denmark
关键词
D O I
10.1200/JCO.2005.06.219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To analyze thymidylate synthase (TS) and methylenetetrahydrofolate reductase (MTHFR) gene polymorphism with respect to fluorouracil (FU) sensitivity. Patients and Methods The study included a retrospective analysis of 88 patients with metastatic colorectal cancer and a prospective trial with 51 patients also with measurable metastases. All patients were treated with FU and leucovorin. The analysis of gene polymorphism was performed on normal intestinal tissue and lymphocytes. Results The response rate was significantly higher in patients with TS3R/3R or MTHFR677TT gene polymorphism compared with the other groups. The difference of response rate translated to a difference in time to progression. Similar results were observed in the retrospective analysis and the prospective confirmatory trial. Conclusion The analysis of gene polymorphism allows delineation of a group of patients (30%) with a response rate to a single drug of approximately 50%. This information should be used in the design of tailored treatment.
引用
收藏
页码:1365 / 1369
页数:5
相关论文
共 20 条
[1]  
Cohen V, 2003, CLIN CANCER RES, V9, P1611
[2]   Thymidylate synthase expression in colorectal cancer:: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy [J].
Edler, D ;
Glimelius, B ;
Hallström, M ;
Jakobsen, A ;
Johnston, PG ;
Magnusson, I ;
Ragnhammar, P ;
Blomgren, H .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1721-1728
[3]   Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy:: Phenotypic and genotypic analyses [J].
Etienne, MC ;
Chazal, M ;
Laurent-Puig, P ;
Magné, N ;
Rosty, C ;
Formento, JL ;
Francoual, M ;
Formento, P ;
Renée, N ;
Chamorey, E ;
Bourgeon, A ;
Seitz, JF ;
Delpero, JR ;
Letoublon, C ;
Pezet, D ;
Milano, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2832-2843
[4]   Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity [J].
Etienne, MC ;
Ilc, K ;
Formento, JL ;
Laurent-Puig, P ;
Formento, P ;
Cheradame, S ;
Fischel, JL ;
Milano, G .
BRITISH JOURNAL OF CANCER, 2004, 90 (02) :526-534
[5]   A CANDIDATE GENETIC RISK FACTOR FOR VASCULAR-DISEASE - A COMMON MUTATION IN METHYLENETETRAHYDROFOLATE REDUCTASE [J].
FROSST, P ;
BLOM, HJ ;
MILOS, R ;
GOYETTE, P ;
SHEPPARD, CA ;
MATTHEWS, RG ;
BOERS, GJH ;
DENHEIJER, M ;
KLUIJTMANS, LAJ ;
VANDENHEUVEL, LP ;
ROZEN, R .
NATURE GENETICS, 1995, 10 (01) :111-113
[6]   Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer:: a prospective randomised trial [J].
Glimelius, B ;
Jakobsen, A ;
Graf, W ;
Berglund, Å ;
Gadeberg, C ;
Hansen, P ;
Kjaer, M ;
Brunsgaard, N ;
Sandberg, E ;
Lindberg, B ;
Sellström, H ;
Lorentz, T ;
Påhlman, L ;
Gustavsson, B .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (05) :674-678
[7]   A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil [J].
Iacopetta, B ;
Grieu, F ;
Joseph, D ;
Elsaleh, H .
BRITISH JOURNAL OF CANCER, 2001, 85 (06) :827-830
[8]  
Ishida Y, 2002, ANTICANCER RES, V22, P2805
[9]  
Jakobsen A, 2002, ACTA ONCOL, V41, P525
[10]  
Kawakami K, 2001, CLIN CANCER RES, V7, P4096